Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-19
2005-04-19
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S359500
Reexamination Certificate
active
06881749
ABSTRACT:
Pyranoindazoles are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of the present invention.
REFERENCES:
patent: 4690931 (1987-09-01), Wick et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5494928 (1996-02-01), Bös
patent: 5561150 (1996-10-01), Wichmann
patent: 5571833 (1996-11-01), Kruse et al.
patent: 5578612 (1996-11-01), Macor et al.
patent: 5646173 (1997-07-01), Bös et al.
patent: 5874477 (1999-02-01), McConnell et al.
patent: 5889052 (1999-03-01), Klimko et al.
patent: 5902815 (1999-05-01), Olney et al.
patent: 6245796 (2001-06-01), Maeno et al.
patent: 6548493 (2003-04-01), Robichaud et al.
patent: 6552017 (2003-04-01), Robichaud et al.
patent: 6696476 (2004-02-01), Chen et al.
patent: 6713471 (2004-03-01), Robichaud et al.
patent: 20040034015 (2004-02-01), Robichaud et al.
patent: 0771563 (1997-05-01), None
patent: 0990650 (2000-04-01), None
patent: WO 9220338 (1992-11-01), None
patent: WO 9413275 (1994-06-01), None
patent: WO 9733579 (1997-09-01), None
patent: WO 9818458 (1998-05-01), None
patent: WO 9830548 (1998-07-01), None
patent: WO 9831354 (1998-07-01), None
patent: WO 9856768 (1998-12-01), None
patent: WO 0012475 (2000-03-01), None
patent: WO 0012510 (2000-03-01), None
patent: WO 0016761 (2000-03-01), None
patent: WO 0035922 (2000-06-01), None
patent: WO 0044753 (2000-08-01), None
patent: WO 0170701 (2001-09-01), None
patent: WO 0183487 (2001-11-01), None
Osborne, et al. “Do Beta-Adrenoceptors and Serotonin 5-HT1AReceptors Have Similar Functions in the Control of Intraocular Pressure in the Rabbit?”Ophthalmologica,vol. 210, pp. 308-314 (1996).
Wang, et al., “Effect of 5-methylurapidil, an α1a-adrenergic antagonist and 5-hydroxytryptamine1aagonist, on aqueous humor dynamics in monkeys and rabbits”Current Eye Research,vol. 16(8) pp. 769-775 (1997).
IOVS,Aqueous Humor Dynamics I,vol. 39(4), S488, 2236-B93, (1998).
Fiorella, “Role of 5-HT2Aand 5-HT2Creceptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives,”Psychopharmacology,vol. 121:357-363, 1995.
Frigerio, et al., “Oxidation of Alcohols with o-Iodoxybenzoic Acid (IBX) in DMSO: A New Insight into an Old Hypervalent Iodine Reagent”J. Org. Chem.60, pp 7272-7276 (1995).
Portal et al. “The Synthesis of Benzo (b) Thieno and Benzo (b) Furo Indazole Derivatives. The Report of Three Novel Heterocyclic Systems.”Anales Assoc. Quim. Argentina59, 69-76 (1971).
Clark et al., “Heterocyclic Studies. Part 42. Pyrimido[5,4-d][1,2,3]triazines and some Related Tricyclic Compounds”J. Chem. Soc., Perkinsvol. 1, pp. 1475-1481 (1984).
Lown et al., “Formation of Novel 1,2-Oxathietanes from 2-Chloroethyl Sulfoxide Precursors and Their Reactions in Solution, Including Formal [σ2s + σ2a] Cycloreversions and Rearrangements”J. Amer. Chem. Soc.,vol. 108, No. 13, pp. 3811-3818 (1986).
Benson, Jr. et al., “N-Alkyl-5,5-dimethyl-2-oxomorpholin-3-YI Radicals. Characterization and Reaction with Molecular Oxygen.”J. Amer. Chem. Soc.vol. 113, pp. 8879-8886 (1991).
Wentland et al., “Synthesis and Bacterial DNA Gyrase Inhibitory Properties of a Spirocyclopropylquinolone Derivative”J. Med. Chem.,vol. 31, pp. 1694-1697 (1988).
Johnson, “Reaction of Aliphatic Amines with Formaldehyde and Nitroparaffins. II. Secondary Amines,”J. Amer. Chem. Soc.,vol. 68, pp. 12-14 (1946).
Sequeria et al., “Synthesis of Fused Indazole Derivatives”Indian J. Chem.26B, pp. 436-439 (1987).
Grandolini et al., “92/New Heterocyclic Ring Systems from α-Hydroxymethyleneketones. VII. Furoindazoles and Furobenzisoxazoles,”Gazz. Chim Ital.vol. 106, pp. 1083-1094 (1976).
Plug et al., “Synthesis of Novel Annulated Ellipticines via Claisen Rearrangement Reactions,”Tetrahedron Lett.vol. 33, pp. 2179-2182 (1992).
Macor et al., “The Synthesis of Conformationally/Rotationally Restricted Analogs of the Neurotransmitter Serotonin,”Tetrahedron Lett.vol. 35, pp. 45-48 (1994).
Macor et al., “Studies towards understanding the mechanism of the unusual rearrangmetn of certain 5-proparglyoxyindoles,”Tetrahedron Lett.vol. 41, pp. 3541-3545 (2000).
Johnson et al., Binding to the Serotonin 5-HT2 Receptor by the Enantiomers of 125I-DOI,Neuropharmacology,vol. 26, pp. 1803-1806 (1987).
Bowen et al., “Nonlinear regression using spreadsheets,”Trends Pharmacol. Sci.,vol. 16, pp. 413-417 (1995).
Gorvin, “Aromatic nitro-group displacement reactions.”J. Chem. Res., Synop.(4), pp. 88-89, (1991) (Abstract).
International Search Report for PCT/US02/16861 dated Dec. 11, 2002.
Chen Hwang-Hsing
May Jesse A.
Severns Bryon S.
Alcon Inc.
Kilyk & Bowersox P.L.L.C.
Powers Fiona T.
LandOfFree
Pyranoindazoles and their use for the treatment of glaucoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyranoindazoles and their use for the treatment of glaucoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyranoindazoles and their use for the treatment of glaucoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3436205